Document is current
Any future updates will be listed below
-
Authors
Thierry, Isabelle P.
Muller, Steven A.
Baas, Annette F.
Dooijes, Dennis
van Loon, R. Laura E.
Schoemaker, Angela E.
van der Harst, Pim
Oerlemans, Marish I. F. J.
Baars, Hubert F.
Hassink, Rutger J.
Asselbergs, Folkert W.
van Tintelen, J. Peter
te Riele, Anneline S. J. M.
-
Funding
Funding for this research was provided by:
HORIZON EUROPE Framework Programme (#101115536)
ZonMw (Off Road Grant 2021)
Netherlands Heart Institute (Young Talent Program Predict2)
- License Information
-
More Information
Article History
Accepted: 2 December 2024
First Online: 20 January 2025
Declarations
:
: I.P. Thierry, S.A. Muller, A.F. Baas, D. Dooijes, R.L.E. van Loon, A.E. Schoemaker, M.I.F.J. Oerlemans, H.F. Baars, R.J. Hassink, F.W. Asselbergs and J.P. van Tintelen declare that they have no competing interests. A.S.J.M. te Riele is a consultant for Tenaya Therapeutics, BioMarin and Rocket Pharmaceuticals for unrelated work. P. van der Harst is the Editor-in-Chief of the Netherlands Heart Journal.
: For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.
